Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

ty is a public health crisis, with more than 70 million Americans considered to be obese, according to the Centers for Disease Control. It is a chronic disease that is linked to serious medical conditions such as Type 2 diabetes, heart disease, blood pressure, stroke, depression and some forms of cancer. Obesity results from an energy imbalance associated with various environmental, behavioral and genetic factors making it a difficult and complicated condition to treat. However, there is a growing understanding of how the central nervous system regulates appetite and metabolism as well as the mechanisms that limit weight loss over time. This understanding is the basis of new strategies in drug development that we believe have the potential to change the way obesity is treated.

About Contrave

Contrave is an investigational oral weight loss medication with a unique mechanism of action that works at two levels within the central nervous system: one designed to control the balance of food intake and metabolism and another designed to control food preference, reward and cravings. We believe that Contrave may be the first treatment for obesity to target these reward centers in the central nervous system. Based on clinical trials completed to date, Contrave is believed to initiate and sustain significant weight loss over one year of treatment by reducing appetite, increasing metabolism and allowing the body to continue losing weight by offsetting its natural tendency to fight back and slow down the weight loss process.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 AudioNotch is the ... therapy for the treatment of tinnitus. Patients listen to ... and over a period of weeks to months, their tinnitus ... in two forms: Notched Music and Notched White Noise. Now, ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... On Monday, December 1, 2008, at,8:30 a.m. ... (CTI) (Nasdaq and MTA: CTIC) management team will ... Spectrum Pharmaceuticals of,Irvine, California to jointly market and ... slides, and the slides are also available for ...
... Humans Age is the title of an 8-minute documentary film narrated ... product designed to promote healthy aging. , ... , http://www.prnewswire.com/mnr/longevinex/35829/ , , ... aging -- that humans begin to age biologically only after full ...
... -- Plastics are everywhere in our modern world, largely ... durable, but lightweight and easily workable. One of their ... rather than break when put under stress - is ... as "plastic flow", allows many plastics to change shape ...
Cached Biology Technology:Video: 8-Minute Film Documentary Explores Why Humans Age 2Fast molecular rearrangements hold key to plastic’s toughness 2Fast molecular rearrangements hold key to plastic’s toughness 3
(Date:4/17/2014)... Current Biology on April 17 have discovered ... Brazilian insects, which represent four distinct but related species ... example of an animal with sex-reversed genitalia. , ... animals, Neotrogla is the only example in ... Yoshizawa from Hokkaido University in Japan. , During copulation, ...
(Date:4/17/2014)... new way the immune system may fight cancers and ... immune cells to treat illness. , The research, in ... of "neighborhood police" specialized squads of defenders that ... an entire city, the body. , Scientists at Washington ... that the liver, skin and uterus each has dedicated ...
(Date:4/16/2014)... two new species of yellow-shouldered bats have been unearthed by scientists ... of Natural History and described in the open access journal ... Sturnira are part of a recent discovery of three ... still waiting to be officially announced. , Up until recently the ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Some immune cells defend only 1 organ 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... U.S., China, Australia and Japan today reports having sequenced and ... to have a powerful genetic system that repairs genetic defects, ... more than 86 percent of the nearly 27,000 genes of ... China and elsewhere as a symbol of spiritual purity and ...
... landmark cancer study published online in Nature , ... longstanding mystery about how pancreatic tumor cells feed themselves, ... disease with few treatment options. Pancreatic cancer kills nearly ... cancer death. The life expectancy for most people diagnosed ...
... at the Institute for Systems Biology in Seattle (USA) ... the University of Luxembourg have jointly developed a revolutionary ... team of Dr. Aime Dudley from the ISB and ... the renowned scientific journal Nature Methods on ...
Cached Biology News:Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 2Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 3Scientists sequence genome of 'sacred lotus,' which likely holds anti-aging secrets 4Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target 2Family trees for yeast cells 2
... E.Coli glycerol stocks contained in standard 96-well ... clones with approximately 5,000 clones per plate. ... plate well, the corresponding subplate is screened ... the positive well(s). Cells from a positive ...
... system designed for flexibility and routine operation. ... ion lens, true hyperbolic quadrupole and high-speed ... widest range of sample types and applications. ... as standard Agilents unique ShieldTorch System, which ...
... LUMIstar OPTIMA is a fully automated ... for the widest possible range of ... Reporter gene assays luciferase, -galactosidase, gene ... esters, dioxetanes..) Luminescent Immunoassays ...
... Quidel's depleted sera are specifically depleted of ... of the depleted protein, the alternative and ... are therefore ideal for the detection and ... sera have been used to assess complement ...
Biology Products: